Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.46 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.45 |
| ▸ | PRPS1 | P60891 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | APAF1 | O14727 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3038500 | 0.92 | CSNK2A2 (0.53) | CSNK2A2CSNK2A1PTGS2PRPS1ADORA2B | |
| SCHEMBL3035802 | 0.80 | FGFR1 (0.50) | CSNK2A2CSNK2A1PTGS2ADORA2BSMN1; SMN2 | |
| SCHEMBL3045527 | 0.80 | FGFR1 (0.50) | CSNK2A2CSNK2A1PTGS2ADORA2BSMN1; SMN2 | |
| SCHEMBL4972896 | 0.79 | KDM4E (0.41) | CSNK2A2CSNK2A1PTGS2EGLN3SMN1; SMN2 | |
| SCHEMBL3041706 | 0.78 | EGLN3 (0.60) | EGLN3APAF1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3042764 | 0.77 | PTGS2 (0.48) | CSNK2A2CSNK2A1PTGS2ADORA2BEGLN3 | |
| SCHEMBL14291770 | 0.76 | PTGS2 (0.49) | CSNK2A2CSNK2A1PTGS2ADORA2BEGLN3 | |
| SCHEMBL306478 | 0.75 | PTGS2 (0.46) | CSNK2A2CSNK2A1PTGS2ADORA2BEGLN3 | |
| SCHEMBL306565 | 0.75 | PTGS2 (0.48) | CSNK2A2CSNK2A1PTGS2PRPS1ADORA2B | |
| SCHEMBL308328 | 0.75 | PTGS2 (0.48) | CSNK2A2CSNK2A1PTGS2ADORA2BEGLN3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | ASTRAZENECA AB (SE) | 2008-01-17 | — | — | US | disclosed |
| EP-1797067-A1 | NEW HETEROCYCLIC AMIDES | AstraZeneca AB (SE) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006033620-A1 | NEW HETEROCYCLIC AMIDES | ASTRAZENECA AB (SE) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015222-A1 | New Heterocyclic Amides | AADAC, AVPR2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CSNK2A2 1386/4885CSNK2A1 1520/4885PTGS2 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.